Mixed trend on the daily chart: below its 200-day average, above its 50-day · 50-day below the 200-day · SuperTrend up since Sep 30 · inside the Ichimoku cloud · RSI 53 · MACD above its signal
None of the 29 investors followed here reported a position in HLS.TO in their latest filing.
From each investor's quarterly 13F filing with the SEC: positions at the quarter's end, reported up to 45 days later. All investors
| Date | Insider | Transaction | Shares | Value |
|---|---|---|---|---|
| Sep 7, 2026 | Haroun (Daniel)Senior Officer of Issuer | Acquisition in the public market at price 2.78 per share. | 2K | $5.56K |
| Aug 31, 2026 | Hanna, John GordonDirector of Issuer | Acquisition in the public market at price 2.68 per share. | 2K | $5.37K |
| Aug 27, 2026 | Hls Therapeutics Inc.Issuer | Redemption, retraction, cancelation, repurchase at price 2.64 per share. | 2K | $5.28K |
| Aug 27, 2026 | Hls Therapeutics Inc.Issuer | — | 2K | — |
| Aug 26, 2026 | Hls Therapeutics Inc.Issuer | Redemption, retraction, cancelation, repurchase at price 2.66 per share. | 2K | $5.32K |
| Aug 26, 2026 | Hls Therapeutics Inc.Issuer | — | 2K | — |
| Aug 25, 2026 | Hls Therapeutics Inc.Issuer | Redemption, retraction, cancelation, repurchase at price 2.70 per share. | 2K | $5.39K |
| Aug 25, 2026 | Hls Therapeutics Inc.Issuer | — | 2K | — |
| Aug 24, 2026 | Hls Therapeutics Inc.Issuer | Redemption, retraction, cancelation, repurchase at price 2.67 per share. | 2.1K | $5.56K |
| Aug 24, 2026 | Hls Therapeutics Inc.Issuer | — | 2.1K | — |
| Aug 23, 2026 | Hls Therapeutics Inc.Issuer | Redemption, retraction, cancelation, repurchase at price 2.66 per share. | 2K | $5.33K |
| Aug 23, 2026 | Hls Therapeutics Inc.Issuer | — | 2K | — |
| Aug 20, 2026 | Hls Therapeutics Inc.Issuer | Redemption, retraction, cancelation, repurchase at price 2.74 per share. | 2K | $5.48K |
| Aug 20, 2026 | Hls Therapeutics Inc.Issuer | — | 2K | — |
| Aug 19, 2026 | Hls Therapeutics Inc.Issuer | Redemption, retraction, cancelation, repurchase at price 2.73 per share. | 2.1K | $5.67K |
| Aug 19, 2026 | Hls Therapeutics Inc.Issuer | — | 2.1K | — |
| Aug 19, 2026 | Millian (Craig Stuart)Director of Issuer | Acquisition in the public market at price 2.73 per share. | 500 | $1.36K |
| Aug 18, 2026 | Hls Therapeutics Inc.Issuer | Redemption, retraction, cancelation, repurchase at price 2.73 per share. | 2K | $5.46K |
| Aug 18, 2026 | Hls Therapeutics Inc.Issuer | — | 2K | — |
| Aug 17, 2026 | Hls Therapeutics Inc.Issuer | Redemption, retraction, cancelation, repurchase at price 2.71 per share. | 2K | $5.42K |
| Year | Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Year |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 | -6.8 | 0.2 | -2.9 | 6.4 | -1.3 | -3.9 | -4.8 | -10.7 | 12.0 | -2.4 | −14.9% | ||
| 2025 | 2.3 | 4.2 | 11.0 | -8.8 | 17.0 | -3.2 | 4.8 | 6.6 | 6.5 | -2.3 | -11.1 | -2.8 | +22.6% |
| 2024 | 5.1 | 0.7 | -4.3 | 16.3 | -20.0 | -9.9 | -2.4 | 1.5 | 13.3 | -11.2 | 8.1 | 8.9 | −0.5% |
| 2023 | -4.9 | -10.2 | -25.0 | -11.1 | -24.8 | 36.8 | 9.4 | -26.2 | 7.5 | 0.8 | -30.8 | 13.2 | −59.8% |
| 2022 | -1.5 | -2.4 | 5.5 | -9.9 | 6.5 | -16.6 | 6.0 | -12.8 | -19.8 | 5.9 | 0.3 | 2.6 | −34.5% |
| 2021 | -9.1 | 11.9 | 6.4 | -0.3 | -6.8 | -6.6 | 0.5 | 9.3 | -1.0 | 3.1 | -15.7 | -6.4 | −16.7% |
| 2020 | -9.8 | -7.4 | -19.0 | 7.2 | 12.6 | -12.7 | -2.5 | -7.0 | -15.0 | 5.1 | 23.2 | -0.8 | −29.4% |
| 2019 | -6.7 | 14.0 | 2.8 | 4.6 | -4.7 | 0.3 | 12.8 | -22.4 | 7.2 | -0.1 | 20.3 | 41.3 | +74.1% |
| 2018 | -18.5 | 2.1 | -3.1 | -7.4 | -5.2 | 67.9 | 12.6 | -2.6 | -3.6 | +25.8% |
No member of Congress has disclosed a HLS.TO trade since 2025.
From House and Senate STOCK Act reports. Members disclose trades, not holdings, as value ranges up to 45 days later, so amounts are estimates and “last move” is a hint at who still holds it, not a position. All recent congress trades
HLS Therapeutics Inc., a specialty pharmaceutical company, acquires and commercializes pharmaceutical products for the treatment of psychiatric disorders and cardiovascular disease in Canada, the United States, and internationally. The company offers Clozaril (clozapine tablets), an atypical antipsychotic to manage symptoms of treatment-resistant schizophrenia; CSAN Pronto device, which enhances and simplifies the mandatory safety blood monitoring process for patients that are prescribed Clozaril; Nilemdo, a bempedoic acid product for cardiovascular risk reduction; Nexlizet, a bempedoic acid and ezetimibe product for cardiovascular risk reduction; and Vascepa, an icosapent ethyl capsule for the treatment of cardiovascular disease. It also distributes MyCare psychiatry lab assays, which are a line of tests that can be processed on analyzers used in laboratory systems to measure the blood levels of the most common antipsychotic drugs, including clozapine, risperidone, quetiapine, aripiprazole, olanzapine, and paliperidone; and MyCare Insite, a point-of-care device that requires only a single drop of blood taken by a finger stick to measure patient drug levels. In addition, the company holds royalty interest in Takeda's Obizur, a porcine recombinant Factor VIII for acquired Hemophilia A. It serves wholesalers and institutions. HLS Therapeutics Inc. is headquartered in Etobicoke, Canada.
Buy / hold / sell counts
No recent headlines.